Biotest AG Revises Revenue, Cash Flow, and ROCE Forecasts for 2024

Biotest AG has updated its financial projections for the year 2024, maintaining its operating profit expectations but revising other key metrics. The company now anticipates a modest revenue growth in the low single-digit percentage range, a reduction from the previously expected high single-digit growth. This includes revenue contributions from technology and development services for Grifols, S.A.

The return on capital employed (ROCE) is forecasted to fall between 5-8%, down from 2023's 12.3%. Additionally, the cash flow from operating activities is expected to be in the negative mid-double-digit million range, contrasting with prior projections of a positive cash flow.

Despite these adjustments, Biotest still projects its EBIT to be between €80 million and €100 million, unchanged from earlier forecasts. This announcement reflects cautious adjustments while maintaining a stable expectation for operational profitability.